PRIMARY OPEN ANGLE GLAUCOMA (POAG)
Clinical trials for PRIMARY OPEN ANGLE GLAUCOMA (POAG) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY OPEN ANGLE GLAUCOMA (POAG) trials appear
Sign up with your email to follow new studies for PRIMARY OPEN ANGLE GLAUCOMA (POAG), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Glaucoma drug trial seeks to slow vision loss
Disease control CompletedThis study tested a drug called Mexidol in 102 adults with moderate to advanced open-angle glaucoma. The goal was to find the best dose to protect vision. Participants received either Mexidol or a placebo, and their visual field was measured over several months.
Matched conditions: PRIMARY OPEN ANGLE GLAUCOMA (POAG)
Phase: PHASE2 • Sponsor: Pharmasoft • Aim: Disease control
Last updated May 17, 2026 11:01 UTC
-
Can a nerve protector slow glaucoma damage?
Disease control CompletedThis study tested a medicine called Mexidol in 80 adults with advanced primary open-angle glaucoma. The goal was to see if it can protect the eye's nerve cells and help control the disease. Researchers measured changes in cell energy and vision over time.
Matched conditions: PRIMARY OPEN ANGLE GLAUCOMA (POAG)
Phase: PHASE4 • Sponsor: Pharmasoft • Aim: Disease control
Last updated May 15, 2026 11:56 UTC